Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter, Managing Editor Bridget Silverman and Editor-in-Chief Nielsen Hobbs consider strategies that incoming President Donald Trump and his team could use to make their promised US Food and Drug Administration reforms (:24), outgoing Center for Drug Evaluation and Research Director Patriza Cavazzoni’s comments about agency staffing and publishing reviews of applications that received complete response letters (12:35), and new application approval patterns in CDER as well as the Center for Biologics Evaluation and Research (21:53).
More On These Topics From The Pink Sheet
- Trump’s US FDA Reforms Need Center Director, Staff Support To Succeed, Former Leaders Say
- Exit Interview: US FDA’s Patrizia Cavazzoni Says CDER Staff In ‘Best Place Possible’
- Innovation Drives Divergence: US FDA Drugs and Biologics Centers Follow Own Trajectories
- US FDA’s Median Review Time Remains Less Than One Year Despite Swell Of Missed Goal Dates
- Clocking The Speed Of US FDA 2024 Novel Approvals
This and other podcasts are available on the Pink Sheet podcast page, as well as the Citeline channel on Apple Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
